Cardinal Analytx Pitch Deck (2019): 14-Slide Series B Deck

Cardinal Analytx, a Stanford Start-X spin-out, presents a data-heavy Series B deck focused on solving the 'cost bloom' problem in healthcare. By predicting which 6% of the population will drive 33% of new high costs, the company demonstrates a clear value proposition for health plans and self-insured employers. The deck is notable for its high-caliber team and board, including John Doerr and Stanford professors, which provides significant institutional credibility. While the deck excels at demonstrating technical superiority over incumbents like Optum and Verscend, it lacks a traditional 'Ask…

Key takeaways

• The company identifies a specific market inefficiency where 6% of the population accounts for 1/3 of next year's new high costs (Slide 3).
• Cardinal Analytx claims 2.5x accuracy over traditional predictive models used in healthcare (Slide 2).
• The product suite is divided into three distinct solutions with average annual prices ranging from $400k to $850k per customer (Slide 4).
• The deck provides a specific case study showing an 8x ROI and $6M in savings for a health plan with 600k lives (Slide 5).
• Competitive benchmarking shows the company's machine learning model achieving a 31% R-Squared value compared to 11-20% for competitors (Slide 8).
• The team and board are exceptionally high-profile, featuring Kleiner Perkins Chairman John Doerr and Stanford faculty (Slide 11).
• The investment roadmap targets a scale-up from 26 million lives covered in 2019 to 50 million lives by 2021 (Slide 13).
• The deck omits a specific 'Use of Funds' breakdown, focusing instead on the macro 'Investment Opportunity' timeline (Slide 13).

Frequently asked questions

What is the core problem Cardinal Analytx solves?

The company addresses the 'cost bloom' in healthcare, where a small percentage of patients (6%) unexpectedly transition from low-cost to high-cost status, accounting for 33% of new annual spending. Traditional models fail to predict these 'jumps' in cost, leading to missed opportunities for clinical intervention and financial mispricing for health plans.

How does Cardinal Analytx generate revenue?

The company utilizes a B2B SaaS model targeting health plans and self-insured employers. Slide 4 outlines three primary solutions: Cost Bloom Intervention ($850k/year), Steerage Precision ($400k/year), and Risk Assessment ($600k/year). These high six-figure annual contracts indicate a high-touch enterprise sales motion.

Who are the primary competitors mentioned in the deck?

The deck explicitly names incumbents in the 'Traditional Predictions' category, including Optum (ERG), Verscend (DxCG), Milliman, and Lexis Nexis. It positions itself as superior by using 'Machine Learning Predictions with Drivers and Actions,' a category it shares with few others like KenSCI and Cyft.

What traction did the company have at the time of the Series B?

At the time of the 2019 Series B, the company reported 2 paid customers, 8 customers with MSAs, and a pipeline of 20 potential customers. They were covering 21 million lives and had grown their team to 28 employees following 4 years of R&D.

What is the significance of the Stanford connection?

The company is a spin-out from Stanford Start-X. Both founders, Nigam Shah and Arnold Milstein, are Stanford Professors of Medicine. This academic pedigree is used to validate the '2.5x accuracy' claim and the proprietary nature of their machine learning algorithms.

Cardinal Analytx pitch deck: the facts

Company

Cardinal Analytx

Year

2019

Stage

Series B

Slides

14

Sector

Software

Cardinal Analytx pitch deck PDF

The full Cardinal Analytx deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Cardinal Analytx Solutions (later rebranded as Prealize Health) pitch deck was used for

This deck is Cardinal Analytx Solutions’ 2019 **Series B** fundraising presentation, a 14‑slide pitch used to raise a **$22M** round for its healthcare predictive analytics platform focused on “cost bloom” and rising‑risk members. The company is a Stanford StartX spin‑out that applies machine learning to predict future healthcare cost spikes and high‑risk members, selling multi‑product solutions (Cost Bloom Intervention, Steerage, Precision Risk Assessment) to health plans and insurers. At the time of the Series B, the deck highlights 4 years of R&D, 3 products, 2 paid customers, additional customers with MSAs, 21M covered lives, and a data‑heavy ROI story for risk‑bearing health plans. The round closed in May 2019 and was led by John Doerr (Kleiner Perkins), with strategic investors GuideWell Mutual Holding Corporation, Blue Shield of California, and Premera Blue Cross.

Business model: B2B healthcare predictive analytics platform selling AI-enabled risk prediction and cost management software to health plans and insurers.

Round

Series B

Year

2019

Raised

$22M Series B in May 2019.

Lead investor

John Doerr (Kleiner Perkins)

Investors

John Doerr (Kleiner Perkins), GuideWell Mutual Holding Corporation, Blue Shield of California, Premera Blue Cross, Cardinal Partners (earlier round and ongoing backer), Stanford‑StartX Fund (earlier round and ongoing backer)

Headquarters

Palo Alto, California

Industry

Healthcare analytics / Health IT / AI-enabled population health management.

Raising: Series B growth capital to scale its AI‑enabled predictive analytics platform for health plans and proactive care solutions.

Total funding: Approximately $28M total funding, including a $6.1M Series A and a $22M Series B, as reported by multiple funding trackers and press coverage.

Use of funds as presented: Support hiring and continued innovation of AI‑enabled predictive analytics and proactive care solutions for health plans and insurers.

What happened after the Cardinal Analytx Solutions (later rebranded as Prealize Health) deck

Cardinal Analytx Solutions used this 2019 Series B deck to secure a $22M round and subsequently expanded its payer partnerships and product footprint, later rebranding as Prealize Health to reflect its focus on proactive, AI‑driven care enablement for health plans.

• Closed a $22M Series B funding round in May 2019, led by John Doerr with strategic investors GuideWell Mutual Holding Co
• Earlier raised a $6.1M Series A round led by Cardinal Partners, with participation from Premera Blue Cross and the Stanf
• Entered payer partnerships including Premera Blue Cross (Cost Bloom predictive modeling) and Optima Health (AI‑enabled r
• Rebranded from Cardinal Analytx Solutions to Prealize Health, emphasizing AI that connects predictions to proactive care

What the Cardinal Analytx Solutions (later rebranded as Prealize Health) deck got right

• Clear and compelling problem framing around cost bloom and rising risk. The deck articulates a highly focused, quantifiable problem—6% of the population driving one‑third of new high costs—framed around “cost bloom” and rising risk, which resonates strongly with health plans worried about unexpected cost spikes.
• Strong origin story and technical credibility via Stanford StartX spin‑out. Cardinal Analytx positions itself as a Stanford StartX spin‑out with 4 years of R&D, leveraging academic research and machine learning expertise, which enhances credibility for complex AI models in healthcare.
• Well‑defined product suite with explicit enterprise pricing. The deck presents a multi‑product suite—Cost Bloom Intervention, Steerage, Precision Risk Assessment—with specific annual price points per customer (e.g., $850k and $400k), signaling a thought‑through monetization model tied to payer value.
• Early but tangible commercial traction and scale of lives covered. Traction metrics in the breakdown (2 paid customers, additional MSAs, 21–26M lives covered, 28 employees) show that the company has moved beyond pilot stage into meaningful commercial deployment across multiple health plans.
• High‑signal strategic investor base among major health plans. Strategic payer investors—GuideWell Mutual Holding Corporation, Blue Shield of California, and Premera Blue Cross—provide validation that major insurers see value in the solution and are willing to back it financially.
• Documented real‑world payer implementations and case studies. Real‑world deployments and case studies, such as Premera’s use of Cost Bloom predictive modeling and Optima Health’s AI‑enabled rising risk program, demonstrate that the solution operates at scale in payer environments, not just in pilots or academic settings.

What could have been stronger

• Limited visibility into revenue and economics in the deck text provided. Despite the data‑heavy story and strong problem framing (6% of the population driving one‑third of new high costs), the slides shown do not present hard financial metrics such as revenue, ARR, unit economics, or margin, limiting an investor’s ability to assess business performance beyond lives covered and customer count.
• Customer status and revenue quality are not clearly differentiated. The OCR text and external breakdown reference 2 paid customers, 8 customers with MSAs, and 21–26M lives covered, but the deck does not clearly distinguish between pilot, contracted, and recurring revenue clients or quantify contract durations and churn risk.
• Risk, compliance, and integration challenges are underdeveloped. The pitch highlights strong clinical and cost prediction capabilities but offers limited detail (in the available text) on regulatory, privacy, and data‑integration risks with health plans, even though these are material issues for AI in healthcare.
• Pricing is stated but ROI proof points are only implied, not quantified on the shown slides. While annual product pricing is listed (e.g., Cost Bloom Intervention at $850k per customer, Steerage at $400k), the deck text we have does not show explicit ROI calculations tied to real case studies, making it harder for investors to validate that the pricing is well‑supported by savings outcomes.

How an investor would read this deck

What draws attention

• Validation that Cardinal Analytx’s AI models reliably identify the 6% of members who will drive one‑third of new high costs, beyond pilot case studies with Premera, Optima Health, and other health plans.
• Quality of commercial traction at the time of the Series B—2 paid customers, additional MSAs, and 21M+ lives covered—and how this converts into recurring ARR and multi‑year contracts.
• Scalability of the three‑product suite (Cost Bloom Intervention, Steerage, Precision Risk Assessment) at stated annual price points of roughly $400k–$850k per customer, and the resulting revenue potential from existing pipeline.
• Defensibility of the Stanford‑derived IP and algorithms, including how the Stanford StartX spin‑out status and academic founders translate into sustainable competitive advantage against other population‑health analytics vendors.
• Impact of the rebrand to Prealize Health on market perception, positioning versus other AI health analytics firms, and its alignment with a proactive care narrative for payers.

Risks that stand out

• Dependence on large health plans and insurers as customers, which may have long sales cycles, complex procurement processes, and significant integration requirements for predictive analytics tools.
• Model performance risk: if the AI predictions of cost bloom and rising risk do not translate into measurable savings or better outcomes in real‑world deployments, payers may be reluctant to renew or expand contracts.
• Competitive risk from other population health analytics and AI vendors targeting similar rising‑risk use cases and offering integrated care‑management platforms to health plans.
• Regulatory and data‑privacy risk associated with large‑scale use of claims and clinical data, including evolving U.S. healthcare data regulations and payer expectations for explainability of AI models.
• Execution risk around scaling from a small base of early customers and pilots to a broad payer customer base, particularly given the technical and implementation complexity implied by 50,000+ variables and advanced machine learning models.

Questions this deck invites

• Can the company provide cohort‑level evidence demonstrating that its Cost Bloom Intervention and related solutions reduced medical spend or improved outcomes for Premera, Optima Health, or other plans compared to matched control groups?
• What percentage of the 21M+ covered lives and 2 paid customers at the time of the Series B were on multi‑year contracts versus pilots or MSAs, and what was the dollar ARR attached to each?
• How do the core predictive models (cost bloom, engagement likelihood, clinical impactibility) perform versus existing payer models and other vendors in terms of AUC, precision/recall, or lift, based on independent validation?
• What is the company’s data‑governance, privacy, and regulatory compliance framework (HIPAA, state privacy laws) for handling claims and clinical data at scale with large health plans?
• How is the $22M Series B being allocated across R&D, go‑to‑market, and customer success, and what specific milestones (clients, ARR, lives covered) are targeted over the next 24–36 months?

What founders can take from the Cardinal Analytx Solutions (later rebranded as Prealize Health) deck

• A clearly quantified problem—such as 6% of the population driving one‑third of new high costs—creates a compelling anchor for the rest of a healthcare AI pitch and helps investors immediately grasp the magnitude of the opportunity.
• Presenting multiple, distinct but related solutions (Cost Bloom Intervention, Steerage, Precision Risk Assessment) with specific annual price points per customer can show both product depth and monetization clarity in a B2B healthcare analytics deck.
• Highlighting a prestigious origin story (Stanford StartX spin‑out) alongside strategic health plan investors (Premera, GuideWell, Blue Shield of California) helps build credibility for complex AI products in conservative healthcare markets.
• Including concrete operating metrics—paid customers, MSAs, pipeline size, employees, lives covered—can reassure investors that an AI healthcare startup has moved beyond lab R&D into commercial scale.
• Using real‑world payer partnerships and case studies (e.g., Premera’s use of Cost Bloom modeling, Optima Health’s rising‑risk program) demonstrates that predictive models are deployed in practice, not just validated in academic settings.
• A rebrand (to Prealize Health) following a major funding round can be used strategically to shift the narrative from pure prediction to proactive care enablement, aligning the brand with the value proposition emphasized in the deck.

Cardinal Analytx Solutions (later rebranded as Prealize Health) pitch deck: common questions

What does Cardinal Analytx do?

Cardinal Analytx Solutions is a Palo Alto‑based, AI‑enabled health insights company that predicts rising healthcare risk and future high‑cost members for health plans and insurers. Its platform focuses on identifying “cost bloom” events—where a small share of members rapidly transition from low‑cost to high‑cost—so plans can intervene earlier to reduce spend and improve outcomes.

How much did Cardinal Analytx raise in its Series B, and who invested?

In May 2019, Cardinal Analytx closed a **$22M Series B** round. The round was led by venture capitalist **John Doerr** (Kleiner Perkins), with participation from **GuideWell Mutual Holding Corporation**, **Blue Shield of California**, and **Premera Blue Cross** as strategic investors.

What traction and metrics does the Cardinal Analytx pitch deck highlight?

The 14‑slide Series B deck shows Cardinal Analytx as a **Stanford StartX spin‑out** with 4 years of R&D, 3 products, and early commercial traction, including 2 paid customers, additional customers under MSAs, and a pipeline of about 20 potential customers, covering roughly 21M lives at that time. It also presents annual pricing for three products (Cost Bloom Intervention, Steerage, Precision Risk Assessment) and a roadmap for scaling lives covered and client count post‑funding.

What was the $22M Series B funding intended to be used for?

According to coverage of the Series B round and subsequent rebrand, Cardinal Analytx (later Prealize Health) planned to use the $22M primarily to expand hiring and continue product innovation around AI‑enabled predictive analytics and proactive care enablement for health plans.

Did Cardinal Analytx change its name or branding after this deck?

Yes. Cardinal Analytx later rebranded as **Prealize Health**, emphasizing its ability to turn predictions into proactive care actions and better member outcomes while lowering costs. The rebrand followed the completion of the $22M Series B round and positioned the company more squarely as an AI‑driven solution for rising‑risk prediction and intervention.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• Cardinal Analytx rakes in $22M for machine learning predictive...
• We got an exclusive look at the pitch deck that buzzy startup Cardinal Analytx used to raise a $22 million round led by top investor John Do
• Cardinal Analytx Closes $22 Million Series B Round - PR Newswire
• Cardinal Analytx, Inc. Asset Profile | Preqin
• Cardinal Partners Leads $6.1M Series A for Cardinal Analytx Solutions
• Cardinal Analytx Rebrands as Prealize to Reflect Power of Solution...
• CASE STUDY Cardinal Analytx Solutions
• Cardinal Analytx Solutions – Funding, Valuation, Investors, News

Cardinal Analytx pitch deck slides

What each slide of the Cardinal Analytx pitch deck says

Slide 2

Cardinal Predict Future Risk and Rising Cost Analytx Significant Healthcare Al Spin-out from Stanford Start-X 4 Years R&D 3 Products 2 Customers Paid 21 Million 2.5x Lives Accuracy ® 21 28 @@Advisors and Board Employees o] & 20 & Customers MSAs v Pipeline Customers Confidential and Proprietary

Slide 3

— Predicting Future Risk and Rising Cost 6% of today's population will account for 1/3 of next year's new high cost . Implement cost $3.5 Trillion 5.5% Annual Healthcare Cost Yearly Cost Growth Rate p effective programs Price for and manage new financial risks Form the provider network for next Smeiovens provders e year's risk Manage capacity for today and tomorrow Increased Risk Bearing and Risk Sharing Strategies ] Confidential and Proprietary c "

Slide 4

Predict the What, Why and When of Tomorrow's Cost Mitigate Rising Risk Steer High Cost Events Predict Total Cost Solution 1: Solution 2: Solution 3: COST BLOOM INTERVENTION STEERAGE PRECISION RISK ASSESSMENT « Cost Bloom, Jump, High Cost « Clinical Event Likelihood « Prospective Risk Score & Claimant Likelihood Cost « Engagement Likelihood « Engagement Likelihood « Concurrent Risk Score & « Event Timing Likelihood Cost « Clinical Impactability Score * Case Selection Optimizer * Cost Bloom, Jump, High Cost * Case Selection Optimizer Claimant Likelihood * Case Summary * Action Plan Recommendation Ave Annual Price Per Ave Annual Price Per Ave Annual Price Per Customer: $850k Customer: $400k R…

Slide 5

— 8x ROI on Highest Impact Cost Blooms — “I felt like it was meant to be for me to reach this member, it was the perfect moment in time” — Care Manager Patient Outcome: 57 year old male with heart conditions, back pain, and opioid dependence was steered to a higher quality lower cost spinal fusion center, a savings of over $20k. Health Plan A Population Health Plan A Cost $880M Total Cost 600k Lives 34% aA $300M Cost Bloom Blind Spot <=] 33% 36k Lives Highest Impact Cases $20M Savings 2.5k Lives I Cost Boom (Newly High Cost) Bl Persistent High Cost 8x ROI $6M or $0.96 PMPM Savings opretary and Confidential Confidential and Proprietary

Slide 6

— Cost Bloom Adoption at a Blues Plan — NY . \ 40% engagement rate (one call with Cost Bloom member) | 26% active engagement rate (multiple calls with member) Qs 75% successful intervention rate for actively engaged

Slide text above is read directly from the Cardinal Analytx deck PDF embedded on this page.

Related fundraising guides (24)

• How to Create a Financial Slide With No Revenue
• Tesla Pitch Deck Breakdown
• How to Create a Pitch Deck in Google Slides That Actually Gets Funded
• The Ideal Pitch Deck Length: A 13-Slide Guide to Getting Funded
• The Real Cost of a Pitch Deck
• The Pitch Deck Summary Slide: Your First Impression With Investors
• The Founder's Guide to the Investor Pitch Deck
• Pitch Deck Sharing: The Founder's Guide to Tools and Analytics
• How to Design a Pitch Deck Cover That Gets Your Deck Opened
• Revolut Pitch Deck Breakdown
• A Founder's Guide to Pitch Deck Design That Actually Closes
• An Investor-Ready Advertising Plan for Early-Stage Founders
• Coinbase 2012 Pitch Deck Breakdown: A Masterclass in Simplicity
• How Many Charts Do You Need In A Pitch Deck?
• The Founder's Sales Plan Template That Actually Drives Revenue
• How to End Your Pitch: A Guide to the Final Slides, Q&A, and Closing
• How VCs Actually Read a Pitch Deck
• Intercom Pitch Deck Breakdown: How to Sell a Category-Defining Vision
• How To Share Your Pitch Deck Without an NDA
• A Founder's Guide to Pitch Deck Flow That Closes Rounds
• Tinder (Match Box) Pitch Deck Breakdown
• Your Pitch Deck's Only Job Is to Get the Next Meeting
• How to Calculate Your Fundraising Ask and Use of Funds
• The Founder's Guide to Fundraising Materials: From Pitch Deck to Data Room

This deck's categories (3)

• Healthtech & Biotech Pitch Deck Examples
• AI & Machine Learning Pitch Deck Examples
• Series A & Series B Pitch Deck Examples

Decks from the same year (1)

• 2019 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with C

Decks in the same category (12)

• Oscar Health Pitch Deck Breakdown
• AKO Smart Technologies Pitch Deck Breakdown: Real Trial Data, and a Budget That Contradicts It
• Slope Pitch Deck Breakdown: Solving the Clinical Trial Supply Chain Crisis
• Sollis Health Pitch Deck Breakdown: Selling High-Acuity Concierge Medicine
• MedArrive Pitch Deck Breakdown: Leveraging EMS Networks for In-Home Care Delivery
• Twin Health Pitch Deck Breakdown: A Clinical Masterclass in Series C Storytelling
• AccuRx Pitch Deck Breakdown: Dominating NHS Communication with a 96% Market Share
• Akido Labs Pitch Deck Breakdown: Solving Healthcare Data Silos with a Human-Centric Narrative
• Aurion Biotech Pitch Deck Breakdown: Scaling Cell Therapy for Global Blindness
• Kensho Health Pitch Deck Breakdown: A $3.5M Seed Round Built on Provider Supply and Evidence
• WellTrack Pitch Deck Breakdown: A 7-Slide Masterclass in Minimalist Traction
• Whylab Pitch Deck Breakdown: Selling the Digital Gym for Mental Fitness

More pitch deck teardowns (16)

• Capalo AI Pitch Deck Teardown: Optimizing Virtual Power Plants with AI-Driven Trading
• Capdesk Pitch Deck Breakdown: A Masterclass in Market Timing and European Expansion
• Capital List Pitch Deck Teardown: A B2B Ecosystem Play for the London Startup Scene
• Caracal FR Pitch Deck Teardown: A Healthcare Ecosystem Built on Connected Devices
• Carbon Block Pitch Deck Teardown: Automating the Carbon Offset Audit via Distributed Ledger
• Card Blanch Pitch Deck Breakdown: Consolidating the Wallet into a Single Smart Card
• Card Blanch Pitch Deck Teardown: Consolidating the Wallet for a $460K Angel Round
• Cardiff International Inc. Pitch Deck Teardown: A Conglomerate Strategy for OTC Markets
• Cardiolyse Pitch Deck Teardown: A B2B Cloud Platform for ECG Analytics
• Cardium Therapeutics Pitch Deck Teardown: A Multi-Asset Biotech Portfolio Strategy
• Cardlife Pitch Deck Breakdown: A 2015 Seed Deck Focused on SaaS Sprawl Management
• Cardsly Pitch Deck Teardown: A Pre-1.0 Vision for Dynamic QR Code Networking
• CareAtHomeService.Tech Pitch Deck Teardown: A B2B2C Play for the UK Social Care Market
• Careem Pitch Deck Breakdown: The Hyper-Local Strategy That Beat Uber in the Middle East
• CareerApp Pitch Deck Teardown: A Standardized Approach to Entry-Level Hiring
• CareerDean Pitch Deck Teardown: A Minimalist Approach to Community-Driven Career Advice

Recently published pitch deck teardowns (12)

• Nutriband Inc. Pitch Deck Teardown: A Publicly Traded Play for Abuse-Deterrent Transdermals
• Knowledgeo Pitch Deck Teardown: A Booth-Led Vision for Bridging the Academic-Professional Gap
• Invitae Pitch Deck Teardown: Scaling Genomic Data Through Price Disruption
• NXGH Pitch Deck Teardown: A Multi-Product Fintech and Telecom Roll-up Strategy
• Nyctale Pitch Deck Teardown: Bridging On-Chain Behavioral Data and Traditional Finance
• Ober Pitch Deck Teardown: A Highly Derivative Rideshare Template Analysis
• Osisko Development Pitch Deck Teardown: A Masterclass in Mining Asset Technical Disclosure
• Osisko Development Pitch Deck Teardown: A Deep Dive into North American Gold Asset Scaling
• Obie.ai Pitch Deck Teardown: A Masterclass in Demo Day Minimalism and Traction
• Dataastra Pitch Deck Teardown: A Vertical Integration Strategy for Voice AI
• OfferSavvy Pitch Deck Teardown: A 2014 Vision for Social Commerce and Curation
• Ohos Pitch Deck Teardown: A Data-Driven Case for Disrupting HR Performance Reviews

Browse by topic (1)

• Pitch Deck guides

Fundraising library · Pitch deck examples · Investor directory · Founder database